Cobimetinib
Sign in to save this workspacePrimary targets: MEK1, MEK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.644
CATDS
0.048
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Cobimetinib. Strongest target: MEK1 at 73.5% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | MEK1 | 73.5% | 26.4% |
| 2 | MEK2 | 59.8% | 40.2% |
| 3 | TNIK | 30.5% | 69.5% |
| 4 | MINK_MINK1 | 21.7% | 78.3% |
| 5 | ERN1_IRE1 | 21.3% | 78.7% |
| 6 | ALK2_ACVR1 | 21.3% | 78.7% |
| 7 | C_MET | 18.7% | 81.3% |
| 8 | MST3_STK24 | 18.3% | 81.7% |
| 9 | GRK6 | 18.1% | 81.9% |
| 10 | AURORA_B | 17.2% | 82.8% |
| 11 | STK32C_YANK3 | 16.5% | 83.5% |
| 12 | FLT3 | 16.0% | 84.0% |
| 13 | TRPM7_CHAK1 | 15.1% | 84.9% |
| 14 | ALK6_BMPR1B | 14.7% | 85.3% |
| 15 | CK1G2 | 13.9% | 86.1% |
| 16 | COT1_MAP3K8 | 13.4% | 86.6% |
| 17 | TLK1 | 12.6% | 87.4% |
| 18 | CK2A2 | 12.5% | 87.5% |
| 19 | MLK4 | 12.0% | 88.0% |
| 20 | ERK1 | 12.0% | 88.0% |
Selectivity landscape
Where Cobimetinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Cobimetinib.
Atlas insights for Cobimetinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 267.74 | |
| ALLOGRAFT_REJECTION | 773.52 | |
| ANDROGEN_RESPONSE | 216.86 | |
| ANGIOGENESIS | 124.22 | |
| APICAL_JUNCTION | 853.10 | |
| APICAL_SURFACE | 118.05 | |
| APOPTOSIS | 897.25 | |
| BILE_ACID_METABOLISM | 137.13 | |
| CHOLESTEROL_HOMEOSTASIS | 185.18 | |
| COAGULATION | 95.91 | |
| COMPLEMENT | 561.56 | |
| DNA_REPAIR | 282.13 | |
| E2F_TARGETS | 761.82 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 212.54 | |
| ESTROGEN_RESPONSE_EARLY | 438.68 | |
| ESTROGEN_RESPONSE_LATE | 368.41 | |
| FATTY_ACID_METABOLISM | 104.56 | |
| G2M_CHECKPOINT | 692.10 | |
| GLYCOLYSIS | 318.75 | |
| HEDGEHOG_SIGNALING | 105.29 | |
| HEME_METABOLISM | 263.26 | |
| HYPOXIA | 552.81 | |
| IL2_STAT5_SIGNALING | 375.17 | |
| IL6_JAK_STAT3_SIGNALING | 502.94 | |
| INFLAMMATORY_RESPONSE | 567.09 | |
| INTERFERON_ALPHA_RESPONSE | 91.94 | |
| INTERFERON_GAMMA_RESPONSE | 587.88 | |
| KRAS_SIGNALING_DN | 140.28 | |
| KRAS_SIGNALING_UP | 374.62 | |
| MITOTIC_SPINDLE | 827.97 | |
| MTORC1_SIGNALING | 430.18 | |
| MYC_TARGETS_V1 | 467.75 | |
| MYC_TARGETS_V2 | 113.18 | |
| MYOGENESIS | 438.73 | |
| NOTCH_SIGNALING | 92.55 | |
| OXIDATIVE_PHOSPHORYLATION | 175.76 | |
| P53_PATHWAY | 489.28 | |
| PANCREAS_BETA_CELLS | 36.20 | |
| PEROXISOME | 151.00 | |
| PI3K_AKT_MTOR_SIGNALING | 950.22 | |
| PROTEIN_SECRETION | 194.38 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 69.65 | |
| SPERMATOGENESIS | 212.91 | |
| TGF_BETA_SIGNALING | 288.32 | |
| TNFA_SIGNALING_VIA_NFKB | 560.38 | |
| UNFOLDED_PROTEIN_RESPONSE | 219.59 | |
| UV_RESPONSE_DN | 528.04 | |
| UV_RESPONSE_UP | 456.36 | |
| WNT_BETA_CATENIN_SIGNALING | 375.36 | |
| XENOBIOTIC_METABOLISM | 213.44 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.873 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.852 |
| SRR23303752 | — | 0.844 |
| SRR12202498 | — | 0.843 |
| SRR1443713 | GTEX | 0.841 |
Annotations
Sign in to read and post annotations.
Loading…